Friday 6 November 2026 Export CNSY’s income statement to Excel — free account

Cerenome, Inc.

CNSY Healthcare Biotechnology

Cerenome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.2 million, down 10.5% from fiscal 2024.

Revenue: −70.4%
EPS: −311.3%
Free cash flow: −31.5%

Quarter to June 2026, against a year earlier

0.64 0.03 −4.48%

Follow CNSY

Alert me

Market cap: $5.1M
P/E: 0.0×
Fwd P/E: −0.4×
Dividend yield: —
F-score: 3/9
Altman Z: −44.86
Beneish M: −3.46
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 5.09

Revenue ttm 4.20

Net income ttm (26.09)

Free cash flow ttm (23.55)

Net debt Q (2.37)

Valuation

P/E 0.00

Forward P/E (0.36)

Price / sales 1.05

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.81

Financial health

Current ratio Q 1.37

Debt / equity Q 0.00

Interest coverage Q (1,811.40)

Growth

Revenue growth Q −70.43%

Operating income growth Q −488.88%

EPS, this year +38.90%

EPS, next year A +43.94%

Revenue, next year A −28.64%

EPS, past 5 yrs —

EPS, next 5 yrs A +64.48%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 54.36%

10-year low 10-year high

P/B against its own 10 years 56.81%

10-year low 10-year high

EV/Sales against its own 10 years 14.04%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	9	4	13	2
Receivables	—	1	0	2
Inventory	—	—	—	6
Other	1	1	2	1
	10	5	15	12

	2023	2024	2025	Q'26
Payables	7	11	6	8
ST’ Debt	4	3	1	—
Other	—	1	6	1
	11	16	12	9

Compound Annual Growth %

	10y	5y	3y
Sales	0.51%	(5.72%)	185.50%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(10.57%)	5.68%	(14.73%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.96 Actual −1.31

−1.36 −1.25 −1.13 −1.02 −0.91

Q2 FY26 Miss −0.35

Q3 FY26 — Oct 29

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q2 FY26	−0.96	−1.31	Miss by 0.35
Q3 FY26	−0.98	—	Reports 29 October 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.05)	(1.31)	—	—	—
’25	(29.75)	(0.16)	(1.00)	(1.01)	(7.25)
’24	(18.75)	(6.84)	(9.25)	(12.38)	(42.13)
’23	(51.78)	(14.75)	(25.00)	(21.14)	(106.00)
’22	(71.73)	(88.98)	(71.34)	(899.10)	(289.64)
’21	(123.31)	(92.90)	(105.23)	(1.52k)	(415.43)
’20	(104.98)	(170.07)	(147.13)	(275.39)	(697.57)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	0	—	—	—
’25	1	1	1	1	5
’24	2	1	1	1	6
’23	1	2	1	1	5
’22	—	—	0	0	0
’20	0	0	—	—	0
’19	1	0	5	1	7

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(7)	—	—	—
’25	(6)	(6)	(3)	(6)	(21)
’24	(5)	(1)	(4)	(1)	(11)
’23	(6)	(3)	(2)	(2)	(13)
’22	(4)	(3)	(4)	(2)	(13)
’21	(3)	(2)	(2)	(3)	(10)
’20	(2)	(1)	(2)	(3)	(8)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(7)	(8)	—	—	—
’25	(6)	(6)	(3)	(6)	(21)
’24	(5)	(2)	(4)	(1)	(11)
’23	(6)	(3)	(2)	(2)	(13)
’22	(4)	(3)	(4)	(2)	(13)
’21	(3)	(2)	(2)	(3)	(10)
’20	(2)	(1)	(2)	(3)	(9)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	5	3	3	7	0	—	0	5	6	5	4		+1.3%	4	19	45	+105.6%
	Gross margin, %	41.69	5.43	100.00	100.00	100.00	0.00	100.00	100.00	100.00	100.00	100.00		+58.3 pt	Powerpack Cerenome, Inc.’s next three years, line by line Analysts expect revenue to grow 105.6% a year to 2028 — faster than the 1.3% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(22)	(23)	(9)	(3)	(8)	(13)	(20)	(13)	(13)	(22)	(26)		+0.2%
	EBT margin, %	(473.50)	(843.66)	(297.62)	(46.91)	(2,719.80)	0.00	(9,051.34)	(271.04)	(222.84)	(429.43)	(620.70)		+44.1 pt
	Net income	(22)	(23)	(13)	(11)	(8)	(13)	(20)	(13)	(13)	(22)	(26)		+0.2%
Per share, $
Per share, $	Revenue	0.27	13,445.00	6,434.39	1,896.12	25.68	0.00	3.20	39.12	21.93	1.68	0.61		+22.5%
	Earnings	(1.27)	(131,259.60)	(32,617.50)	(3,101.25)	(697.57)	(415.43)	(289.64)	(106.00)	(48.75)	(7.25)	(4.37)		+21.3%
	Cash flow	(1.13)	(90,640.00)	(25,830.31)	(1,600.24)	(714.75)	(318.27)	(185.31)	(102.32)	(39.74)	(6.68)	(3.21)		+21.8%
	Capex	0.00	(6,915.00)	(286.88)	(18.15)	(7.88)	(2.54)	(7.27)	(1.27)	(2.60)	(0.01)	(0.20)		n/m
	Free cash flow	(1.13)	(97,555.00)	(26,117.19)	(1,618.39)	(722.63)	(320.80)	(192.59)	(103.59)	(42.34)	(6.69)	(3.41)		+21.9%
	Book value	0.64	65,000.00	11,270.43	314.30	256.86	335.48	92.07	(10.73)	(33.69)	1.28	0.79		+8.1%
	Shares, m	17	0	0	0	0	0	0	0	0	3	5		(17.3%)
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	—	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	74,274.06	0.27	0.06	0.03	0.10	—	1.03	1.18	1.31	7.65	1.05		8,254.0
	P/B	31,478.25	0.06	0.03	0.19	0.20	—	0.08	0.00	0.00	9.98	0.81		3,498.8
	EV/Sales	74,275.07	4.42	5.65	(0.81)	(0.14)	—	(23.12)	1.02	1.91	6.84	1.55		8,252.3
	EV/FCF	(17,750.99)	(0.61)	(1.27)	0.79	0.09	—	0.90	(0.39)	(0.99)	(1.67)	(0.27)		(1,972.7)
Cash, $m
Cash, $m	Operating cash flow	(20)	(18)	(12)	(6)	(8)	(10)	(13)	(13)	(11)	(21)	(22)		+0.7%
	Capex	0	(1)	0	0	0	0	(1)	0	(1)	0	(1)		n/m
	Free cash flow	(19)	(20)	(12)	(6)	(9)	(10)	(13)	(13)	(11)	(21)	(24)		+0.7%
Balance, $m
Balance, $m	Working capital	6	(4)	(8)	5	1	14	10	(1)	(10)	3	3		(8.3%)
	Net debt	5	3	9	(6)	(1)	(12)	(13)	(5)	0	(12)	(2)		n/m
	Shareholders’ equity	11	13	5	1	3	11	6	(1)	(9)	4	5		(10.6%)
Returns, %
Returns, %	ROA	(60.98)	(80.52)	(54.39)	(48.46)	(46.65)	(78.62)	(88.44)	(75.54)	(144.03)	(195.02)	(214.01)		(134.0) pt
	ROIC	(78.38)	(78.83)	(38.77)	0.00	(386.95)	0.00	0.00	0.00	0.00	0.00	(532.77)		+78.4 pt
	ROE	(190.12)	(222.32)	(165.94)	(358.37)	(393.27)	(193.25)	(234.65)	(522.50)	252.07	903.94	(614.05)		+1,094.1 pt
People
People	Employees	65	37	37	12	12	14	17	20	21	28	—		(8.9%)
	Revenue/emp, $m	0.07	0.07	0.08	0.58	0.03	0.00	0.01	0.25	0.28	0.19	—		+11.2%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ACXP Acurx Pharmaceuticals, Inc.	$5.3M	— (loss-making)	—	—	n/m	−2.36% (below 0%: shrinking)	—	0.00%	Compare
PCSA Heatwurx Inc.	$5.1M	— (loss-making)	—	−64.29% (below 0%: shrinking)	n/m	+20.29% (above 0%: growing)	0.00%	0.00%	Compare
SNTI Senti Biosciences, Inc.	$5.1M	— (loss-making)	— (loss-making)	−98.68% (below 0%: shrinking)	n/m	−7.48% (below 0%: shrinking)	100.00%	(85,229.41%)	Compare
PULM Pulmatrix, Inc.	$5.1M	— (loss-making)	— (loss-making)	−99.86% (below 0%: shrinking)	n/m	+41.26% (above 0%: growing)	100.00%	0.00%	Compare
CNSY Cerenome, Inc.	$5.1M	— (loss-making)	— (loss-making)	−70.43% (below 0%: shrinking)	n/m	−31.46% (below 0%: shrinking)	100.00%	(2,203.65%)
IMNN Imunon, Inc.	$5.1M	— (loss-making)	— (loss-making)	0.00%	n/m	−4.24% (below 0%: shrinking)	0.00%	0.00%	Compare
RVPH Reviva Pharmaceuticals Holdings, Inc.	$5.0M	— (loss-making)	—	—	n/m	+57.80% (above 0%: growing)	—	0.00%	Compare
CDIO Cardio Diagnostics Holdings, Inc.	$5.0M	— (loss-making)	— (loss-making)	+23.79% (above 0%: growing)	n/m	+2.59% (above 0%: growing)	100.00%	(48,193.84%)	Compare
CANF Can-Fite Biopharma Ltd	$4.9M	— (loss-making)	— (loss-making)	−1.18% (below 0%: shrinking)	n/m	+12.63% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$5.1M	—	—	−32.74%	—	+7.61%	50.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 31 March 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	5.57m	4.73m	11.00
2024	1.26m	1.64m	24.00
2023	1.13m	1.57m	37.00

Ownership

Directors and executive officers, together 2.50%

CVI Investments, Inc. 7.20%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Cerenome, Inc. (CNSY) Latest News

4 Nov

Impact 3 · 7:30 AM · GlobeNewswire

Cerenome Secures National In-Network Agreement with Aetna for CNSide®

29 Oct

Impact 4 · 7:30 AM · GlobeNewswire

Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma

27 Oct

Impact 4 · 7:30 AM · GlobeNewswire

Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases

21 Oct

Impact 4 · 7:30 AM · GlobeNewswire

Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™

8 Oct

Impact 4 · 7:30 AM · GlobeNewswire

Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests

6 Oct

Impact 4 · 7:30 AM · GlobeNewswire

Cerenome Launches CNSide® CSF Molecular Profile Tests

30 Sep

Impact 4 · 7:30 AM · GlobeNewswire

Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings

25 Sep

Impact 3 · 7:30 AM · GlobeNewswire

Cerenome to Hold CNSide® Business Update Call on September 30, 2026

22 Sep

Impact 4 · 7:30 AM

Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives

10 Sep

Impact 3 · 7:15 AM

Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment

20 Aug

Impact 3 · 7:30 AM

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

14 Aug

Impact 3 · 4:15 PM

Cerenome Reports Second Quarter 2026 Financial Results and Business Update

13 Aug

Impact 4 · 7:30 AM

Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives

31 Jul

Impact 4 · 8:30 AM

Cerenome Launches as an Integrated CNS Oncology Company

21 Jul

Impact 3 · 7:30 AM

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

16 Jul

Impact 3 · 7:30 AM

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

14 Jul

Impact 3 · 7:30 AM

Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

25 Jun

Impact 4 · 7:30 AM · GlobeNewswire

Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

4 Jun

Impact 3 · 12:17 PM · Proactive Investors

Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform

Impact 3 · 7:30 AM · GlobeNewswire

Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

26 May

Impact 3 · 7:30 AM · GlobeNewswire

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

19 May

Impact 3 · 7:30 AM · GlobeNewswire

Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

15 May

Impact 3 · 5:20 PM · Zacks

Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates

Impact 3 · 4:05 PM

Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

14 May

Impact 4 · 11:39 AM · 24/7 Wall St.

Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6

8 May

Impact 4 · 7:30 AM · GlobeNewswire

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

7 May

Impact 4 · 7:30 AM · GlobeNewswire

Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic

28 Apr

Impact 4 · 7:30 AM · GlobeNewswire

Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

23 Apr

Impact 4 · 7:30 AM · GlobeNewswire

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

21 Apr

Impact 4 · 7:30 AM

Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Cerenome, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 31 March 2026

Chief executive’s pay

Ownership

Cerenome, Inc. (CNSY) Latest News

4 Nov

29 Oct

27 Oct

21 Oct

8 Oct

6 Oct

30 Sep

25 Sep

22 Sep

10 Sep

20 Aug

14 Aug

13 Aug

31 Jul

21 Jul

16 Jul

14 Jul

25 Jun

4 Jun

26 May

19 May

15 May

14 May

8 May

7 May

28 Apr

23 Apr

21 Apr

Stockrow Weekly